| LncRNA |
Compound |
Cancer |
P-value |
Effect |
| ENSG00000257337.2 |
ABT-263 (navitoclax) |
Chronic Lymphocytic Leukemia |
0.046167694 |
Resistant |
| ENSG00000257337.2 |
ABT-263 (navitoclax) |
Breast invasive carcinoma |
0.026067959 |
Sensitive |
| ENSG00000257337.2 |
ABT-263 (navitoclax) |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
0.039503665 |
Sensitive |
| ENSG00000257337.2 |
ABT-263 (navitoclax) |
Colon adenocarcinoma |
0.031817647 |
Sensitive |
| ENSG00000257337.2 |
ABT-263 (navitoclax) |
Pancreatic adenocarcinoma |
0.048874988 |
Sensitive |
